Clinical trials: Prostate Cancer Diagnosis
Prostate Cancer
UCI 03-72 Prostate Cancer Detection by Serum Proteomic Profiling
: Researchers would like to see if a new test called SELDI (Surface Enhanced Laser Desorption Ionization) analysis can predict biopsy results better than PSA tests.
- Trial name
- NCT00355758
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of California, Irvine
Prostate Cancer, Metastatic Cancer
CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.
Identification of biomarkers (Circulating Tumor Cells (CTC), free DNA, Stem Cells and EMT-related antigens) that may be predictive of outcome of activity of cabazitaxel treatment in castration-resistant prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Cancer, Castration-resistant Prostate Cancer, Circulating Tumor Cells
- Trial name
- IRSTB030 (NCT03381326)
- Testing
- blood and FFPE sample collection
- Where
- 9 sites in Italy
- Volunteers
- 104 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Metastatic Prostate Cancer
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
Background: Prednisone and docetaxel have been used successfully in treating patients with prostate cancer, either when used alone or in combination with other agents.
- Trial name
- NCT00942578
- Testing
- Bevacizumab, Lenalidomide, Docetaxel
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Extension to Study of Effects of Pomegranate Extract on Rising PSA Levels After Primary Therapy for Prostate Cancer
High concentrations of anti-oxidants in pomegranate seeds present a potential strategy to delay clinical prostate cancer progression and prolong the interval from primary treatment failure to hormonal ablation.
- Trial name
- NCT00732043
- Testing
- pomegranate extract, pomegranate juice
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Roll International Corporation
Prostate Cancer
Structural Network on Prostate Cancer in the French Greater West Region
The project aims at developing and structuring a network of clinicians, pathologists, and scientists, from the "Grand Ouest" area, most of them already involved in prostate cancer management and research.
- Trial name
- RESCAP (NCT03214315)
- Testing
- Visceral adipose tissue specimen
- Where
- 7 sites in France, Guadeloupe
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Tours
Prostate Cancer
FACBC Outcomes for Post Prostatectomy
Investigators will perform a study with 162 patients in whom there is a strong suspicion of prostate cancer that has returned to the body after having a prostatectomy.
- Trial name
- NCT01666808
- Testing
- FACBC, Radiation therapy
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Emory University
Prostate Cancer
Infective Complications in TP Biopsy Without Antibiotic Prophylaxis
This study is a prospective cohort study to delineate the infective outcomes and incidence after transperineal prostate biopsy with no antibiotic prophylaxis, compared to the existing data on outcomes on patients receiving…
- Trial name
- NCT06359964
- Testing
- Transperineal Biopsy without antibiotics prophylaxis, Transperineal Biopsy with antibiotics prophylaxis
- Where
- Hong Kong
- Volunteers
- 1,753 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer
Artificial Intelligence-based Platform, Integrating Pathologic, Imaging and Molecular Profiles of Prostate Cancer
The goal of this observational study is to use an artificial intelligence-based platform, integrating clinical, pathologic, imaging, genomic and transcriptomic profiles of prostate cancer in order to outperform currently…
- Trial name
- PRISM-AI (NCT06468332)
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita
Prostatic Neoplasms
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
The purpose of this study is to determine the relative bioavailability (rBA; Period 1) and bioequivalence (BE; Period 2 and 3) of various strengths and formulations of niraparib and abiraterone acetate (AA) at steady state under…
- Trial name
- NCT04577833
- Testing
- Niraparib, Abiraterone Acetate (AA), Prednisone
- Where
- 16 sites in United States, Belgium and 9 more
- Volunteers
- 136 people
- Sponsor
- Janssen Research & Development, LLC
Liposarcoma, Prostate Cancer
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy.
- Conditions
- Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- CDK4i (NCT04557449)
- Testing
- PF-07220060, Letrozole, Fulvestrant
- Where
- 39 sites in United States, Argentina and 6 more
- Volunteers
- 430 people
- Sponsor
- Pfizer
Prostate Cancer
The Role of Social Comparisons in Coping and Quality of Life Following a Prostate Cancer Diagnosis
Social comparisons may function as a coping strategy, but their role in coping and quality of life has not been well characterized.
- Trial name
- NCT01176526
- Where
- United States
- Volunteers
- 196 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Prostate Cancer
Early Salvage Therapy for Patients With Advanced Features for Biochemical Relapse After Radical Prostatectomy for Localized Prostate Carcinoma In Correlation With Supposed Molecular-genetic Parameters of Higher Aggressiveness
The primary objective of the trial is to compare the impact and safety of delayed salvage therapy (dSRT, i.e., SRT initiated at PSA values of 0.4-0.5 ng/ml) to those of early salvage therapy (eSRT, i.e., at PSA levels of 0.2…
- Trial name
- ESTABLISH (NCT05232578)
- Testing
- Early salvage radiotherapy (eSRT), Delayed Salvage radiotherapy (dSRT)
- Volunteers
- 380 people
- Sponsor
- General University Hospital, Prague
Prostatic Neoplasm
An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma
Study of Biweekly Docetaxel plus Androgen-Deprivation Therapy (ADT) in Patients with Previously-Untreated, Metastatic, Prostatic Adenocarcinoma
- Trial name
- NCT03061643
- Testing
- Docetaxel, Androgen-Deprivation Therapy (ADT)
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Samsung Medical Center
Breast Cancer, Prostate Cancer
Evaluation of an Apoptotic Test for Predicting Late Toxicities After Radiotherapy in Breast and Prostate Cancer Patients
The primary objective of this study is to evaluate the prediction of late toxicity by the radiation induced CD8 T-lymphocyte apoptosis
- Trial name
- NCT00893035
- Where
- France
- Volunteers
- 885 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Prostate Cancer
CTC Immune Checkpoint
This pilot study will explore the prevalence of expression of four immune checkpoint biomarkers on circulating tumor cells (CTCs) from men with metastatic prostate cancer that are captured by EpCAM via the CellSearch method, and…
- Trial name
- NCT02456571
- Testing
- CTC biomarker expression prevalence
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Duke University
Prostate Cancer
Multifunctional Magnetic Resonance (MR) for Radiotherapy Planning in Prostate Cancer
To determine if functional MRI methods will aid planning of a radiation dose boost within the prostate in patients with prostate cancer potentially improving safety and efficacy.
- Trial name
- NCT01006564
- Testing
- Imaging Investigations (not radiation), Other
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Metastatic Castration Resistant Prostate Cancer
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency…
- Trial name
- CHOMP (NCT04104893)
- Testing
- Pembrolizumab
- Where
- 13 sites in United States
- Volunteers
- 40 people
- Sponsor
- VA Office of Research and Development
Prostate Cancer
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
The objective of this study is to examine the preference weightings in term of risk/ benefit attributes of treatment in physician and prostate cancer patients from different stages of disease.
- Trial name
- NCT05761093
- Where
- Hong Kong
- Volunteers
- 350 people
- Sponsor
- Chinese University of Hong Kong
Prostate Carcinoma
Adaptive Virtual Consultation Tool to Enhance Education and Understanding in Patients with Prostate Cancer
This clinical trial aims to design and validate an adaptive virtual consultation tool (AVCT) for men with prostate cancer (PC). An AVCT utilizes health literacy assessments in combination with learning preferences and individual…
- Trial name
- NCT06016504
- Testing
- Health Education, Informational Intervention, Survey Administration
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Prostate Cancer
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of prostate cancer.
- Trial name
- NCT00025116
- Testing
- gefitinib
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group